Expression of miR-204 and Consequences on Capillarization in Limb Muscles of Patients With COPD

NCT ID: NCT02903043

Last Updated: 2017-05-10

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 100 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-02-28
• Study Completion Date: 2018-02-28

Brief Summary

Limb muscle dysfunction, characterized by loss of capillaries, is amongst the most troublesome systemic consequences of chronic obstructive pulmonary disease (COPD) leading to poor functional status and premature mortality.

One prevailing hypothesis stipulates that modification in the expression of miR-204 leads to change the regulation of angiogenesis in vastus lateralis of patients with COPD when compared to controls.

Detailed Description

The investigators objective is to investigate the impact of COPD on key signaling pathways involved in the muscle angiogenesis. Mild to severe COPD patients and healthy controls will be recruited. All of the investigators patients will undergo a thorough baseline assessment in pulmonary capacity and body composition. Blood sampling and biopsy of the quadriceps will be done. Key proteins and microRNAs of signaling intramuscular pathways involved in angiogenesis will be measured in the quadriceps.

Conditions

Chronic Obstructive Pulmonary Disease

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

COPD patients

Quadriceps biopsies will be done. No drug administration.

No interventions assigned to this group

Healthy controls

Quadriceps biopsies will be done. No drug administration.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• COPD (FEV1/FVC < 0.70)
• Healthy subjects: no evidence of airways obstruction (FEV1/FVC > 0.70 and FEV1 > 0.80 predicted)
• Smoking history > 10 pack-years
• Ex-smoker >6 months

Exclusion Criteria

• Chronic hypoxemia and/or hypercapnia (PaO2 < 60 mmHg or SpO2 < 88% at rest and/or PaCO2 > 45 mmHg)
• Recent exacerbation or oral corticosteroids (< 2 months)
• Recent cancer (< 3 years)
• Diabetes
• Myopathy, neuromuscular, neurological or articular diseases
• Kidney disease
• Other respiratory diseases
• Unstable cardiac disease
• Physical activity score > 9 in the Voorips questionnaire
• BMI > 30

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

Sponsor Role: collaborator

Laval University

OTHER

Sponsor Role: lead

Responsible Party

Annie Dubé

Ph.D.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

François Maltais, MD

Role: STUDY_DIRECTOR

Laval University

Locations

Institut universitaire de cardiologie et de pneumologie de Québec

Québec, , Canada

Countries

Canada

Other Identifiers

MIR-20895

Identifier Type: -

Identifier Source: org_study_id